Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.
about
Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccineAnthrax: A disease of biowarfare and public health importanceIn vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunityRabies virus glycoprotein as a carrier for anthrax protective antigenAnthrax vaccination strategiesContribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccineAnthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challengeImmunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccinesCorrelation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen.Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxIn vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection modelCpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccineBacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelopeOral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigenSearch for correlates of protective immunity conferred by anthrax vaccine.New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Anthrax spores make an essential contribution to vaccine efficacyBacillus anthracis IsdG, a heme-degrading monooxygenaseSalmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge.Protective immunity induced by Bacillus anthracis toxin-deficient strains.Specific activation of dendritic cells enhances clearance of Bacillus anthracis following infection.Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.Systemic but not mucosal immunity induced by AVA prevents inhalational anthraxRecombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen.Detoxified lethal toxin as a potential mucosal vaccine against anthrax.Domain specificity of the human antibody response to Bacillus anthracis protective antigen.Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge modelFrequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbedNovel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies.Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit modelExperimental respiratory anthrax infection in the common marmoset (Callithrix jacchus).Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against Bacillus anthracis Sterne strain.Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
P2860
Q23912118-36BE1426-BFF3-4FD9-872A-9D8F3ACDA8DDQ28082022-CB9AFB55-0586-4598-9CFB-DC2480DDC079Q28383065-C64BF429-E787-44BE-9B3F-C24447D2E8AAQ28391261-BE1D181C-8C12-4DD5-B39A-8BA6560DAF0DQ28392248-E4AC955C-4EB1-4BBC-858E-BA79BCECADABQ28393904-C3C96337-C4F4-4727-9F7F-1D58D966B6D1Q30540217-EC234FE9-E409-4382-B42D-059791083D6AQ30859738-574C3627-39D4-4CFB-BEF2-5B882F8C8643Q31126626-FFDB6E89-5E6F-49D5-8A7E-34E7582E656DQ33230047-2E8E81F0-66E8-47F1-B8C8-2A0D6BDE088CQ33334776-6FE309BC-96D8-4C25-BF00-82DE124315FAQ33396429-91B17E57-4CD6-4E60-8101-6571CC9D8605Q33576071-D197B55D-098C-4C33-8407-46782C253019Q33797188-66399289-A8DB-4FD4-8AF9-B36065C70812Q33855682-17E3D7C0-870C-472E-9868-4E9477FEB093Q33883273-182B0158-944C-4214-8B45-F9805334B139Q34000174-EB24B018-8FFC-464A-9FEE-69AD2B85DE76Q34007168-8002A678-78D4-442B-A861-E91D9F5E08BCQ34066161-2F6BF6FE-E5C9-4AC6-86A1-144438EEB1FBQ34117857-3240CA1C-C7CD-4B52-A7F2-BB749D16894CQ34303390-AB519906-2FF2-4D29-825E-2EACD270419AQ35106528-AE6D9A73-2BEC-4B95-BD86-0118D70D4EADQ35400677-CEFC0980-27E3-406D-8E19-6E14EEAC0D70Q35403794-831D93D4-E65D-484B-93AA-D00BAB5DE062Q35560377-C5E75EBB-D5E7-4F4F-88DF-F060BE5E0A56Q36226066-C3BDC947-C8B1-4CE2-8E1D-4017ED2FE368Q36313906-52A3AAF4-5001-4FAF-8063-45CE75CDC802Q36539063-24F86114-B35C-4FF3-9076-C283049AC47CQ36876723-8C2B06DE-348C-4F2C-A15C-AC7F7E43AD8BQ36980383-DF51044F-8AB2-49D6-A042-403855D3829EQ37033014-7DF67915-A461-4B5C-A129-A6A61A698812Q37191250-390BE504-7FBE-4769-B98C-30505BEE17BEQ37333457-4014C07C-5C4C-4C37-BF39-D12D2D8A75A8Q39143157-1956D25E-77C8-4D86-A1E3-2371C5D97FA1Q40672204-1ED3E99F-1EDE-4609-8735-5F242A2A8C32Q41869569-5967238B-0533-492B-867C-C7C4043E17F2Q44892507-6FD40393-5744-4983-B77A-92D3EDEFAB75Q47135050-FDE0D168-320B-40B9-A0D1-0C57476029D7Q55361721-6E45AD90-E0AA-49BE-A50F-3F49ECF6E3A3
P2860
Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Immunization against anthrax w ...... tigen combined with adjuvants.
@en
type
label
Immunization against anthrax w ...... tigen combined with adjuvants.
@en
prefLabel
Immunization against anthrax w ...... tigen combined with adjuvants.
@en
P2093
P2860
P1476
Immunization against anthrax w ...... tigen combined with adjuvants.
@en
P2093
P2860
P304
P407
P577
1992-02-01T00:00:00Z